ChartRow logo
Sign in
JAZZ
Jazz Pharmaceuticals plc Common Stock (Ireland)Stock · Health Care
$245.84−$3.11 (-1.25%)as of market close, Aug 13, 2026
☾ After hours:$245.85+0.00%3:59 PM ET
CompareLLYUNHJNJABBVISRGTMO

How Jazz Pharmaceuticals plc Common Stock (Ireland) makes money

Period

How does Jazz Pharmaceuticals plc Common Stock (Ireland) make money? This Sankey traces every dollar of revenue through the income statement — into cost of revenue, R&D, SG&A, and taxes — and shows what's left as profit. Pick any fiscal year, recent quarter, or the trailing twelve months. Straight from SEC filings.

Jazz Pharmaceuticals plc Common Stock (Ireland) · FY2025 · year ended 2025-12-31
Revenue$4.3BNet loss$356M · 8%Cost of revenue$0 · 0%Gross profit$4.3B · 100%Operating expenses$4.7B · 110%Other income$74M · 2%R&D$783M · 18%SG&A$1.8B · 42%Other opex$2.1B · 49%Total Oncology$1.1B · 26%Epidiolex Epidyolex$1.1B · 25%Rylaze Enrylaze$403M · 9%Zepzelca$307M · 7%Product & Services Royalties & Contract Revenue$246M · 6%High Sodium AG Oxybate Product Royalty Revenue$212M · 5%Defitelio Defibrotide$199M · 5%Vyxeos$147M · 3%Xyrem$146M · 3%Modeyso$48M · 1%Other Royalties & Contract Revenue$34M · 1%Ziihera$25M · 1%Other revenue$313M · 7%

Each fiscal year from SEC filings. Percentages are share of revenue, so the green profit nodes read directly as gross / operating / net margin. Line items a company doesn't break out are derived from their siblings so the flows balance; small residuals show as “Other.” For informational purposes only.